[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-PCRX":3,"homepage-market-summary":31,"stock-news-PCRX":173},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"PCRX","2026-10-07",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Pacira BioSciences, Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.","829","Brisbane, CA",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":27,"avg_volume_52w":28,"range_52w_percent":29,"record_count":30},25.2,25.05,26,24.99,24.76,0.44,1.78,802724.761173,9785,25.3772,27.66,18.8,677377.0830660398,72.2,3942,{"status":32,"indices":33,"watchlist":76,"sectors":98,"benchmarks":153},"success",[34,41,48,55,61,68],{"symbol":35,"name":36,"price":37,"change":38,"pct_change":39,"is_up":14,"sparkline":40,"date":5},"SPX","S&P 500",7801.77,-17.16,-0.22,"0.0,13.9 2.3,10.5 4.6,12.4 6.9,14.2 9.3,16.0 11.6,11.5 13.9,10.8 16.2,4.8 18.5,4.8 20.8,7.9 23.2,8.0 25.5,6.0 27.8,9.1 30.1,9.8 32.4,10.8 34.7,10.0 37.1,7.0 39.4,4.4 41.7,2.0 44.0,2.9",{"symbol":42,"name":43,"price":44,"change":45,"pct_change":46,"is_up":14,"sparkline":47,"date":5},"NDX","NASDAQ 100",31160.08,-64.4,-0.21,"0.0,15.0 2.3,13.4 4.6,14.8 6.9,16.0 9.3,16.0 11.6,12.9 13.9,11.7 16.2,6.5 18.5,5.0 20.8,6.6 23.2,6.6 25.5,5.8 27.8,7.8 30.1,7.4 32.4,7.0 34.7,6.4 37.1,4.6 39.4,2.9 41.7,2.0 44.0,2.4",{"symbol":49,"name":50,"price":51,"change":52,"pct_change":53,"is_up":14,"sparkline":54,"date":5},"DJI","DOW JONES",51180,-341,-0.66,"0.0,6.3 2.3,2.0 4.6,3.3 6.9,6.0 9.3,11.3 11.6,8.7 13.9,9.5 16.2,6.4 18.5,8.0 20.8,10.9 23.2,12.3 25.5,8.2 27.8,11.2 30.1,12.3 32.4,16.0 34.7,15.8 37.1,13.7 39.4,13.0 41.7,10.8 44.0,13.7",{"symbol":56,"name":57,"price":58,"change":59,"pct_change":39,"is_up":14,"sparkline":60,"date":5},"COMP","NASDAQ Composite",27538.69,-61.2,"0.0,15.1 2.3,12.9 4.6,14.2 6.9,16.0 9.3,16.0 11.6,12.2 13.9,11.3 16.2,6.1 18.5,5.1 20.8,7.7 23.2,7.7 25.5,6.6 27.8,8.7 30.1,8.9 32.4,8.4 34.7,8.3 37.1,5.5 39.4,3.1 41.7,2.0 44.0,2.5",{"symbol":62,"name":63,"price":64,"change":65,"pct_change":66,"is_up":14,"sparkline":67,"date":5},"RUT","RUSSELL 2000",2777,-36.4,-1.29,"0.0,3.5 2.3,2.0 4.6,4.2 6.9,6.7 9.3,8.2 11.6,6.3 13.9,8.0 16.2,6.1 18.5,4.1 20.8,10.7 23.2,11.0 25.5,10.7 27.8,13.1 30.1,14.4 32.4,15.8 34.7,14.3 37.1,11.2 39.4,8.9 41.7,11.4 44.0,16.0",{"symbol":69,"name":70,"price":71,"change":72,"pct_change":73,"is_up":74,"sparkline":75,"date":5},"VIX","CBOE VIX",15.08,0.07,0.47,true,"0.0,2.0 2.3,9.7 4.6,4.9 6.9,4.5 9.3,2.5 11.6,11.3 13.9,13.7 16.2,13.5 18.5,16.0 20.8,12.3 23.2,10.4 25.5,13.5 27.8,8.8 30.1,8.9 32.4,7.8 34.7,7.6 37.1,11.8 39.4,10.9 41.7,12.9 44.0,12.6",[77,84,91],{"symbol":78,"name":79,"price":80,"change":81,"pct_change":82,"is_up":14,"sparkline":83,"date":5},"NVDA","NVIDIA Corp",237.36,-1.88,-0.79,"0.0,16.0 7.3,14.6 14.7,11.8 22.0,8.2 29.3,2.4 36.7,2.0 44.0,4.2",{"symbol":85,"name":86,"price":87,"change":88,"pct_change":89,"is_up":74,"sparkline":90,"date":5},"AAPL","Apple Inc",336.67,3.04,0.91,"0.0,16.0 7.3,9.0 14.7,14.2 22.0,7.7 29.3,9.3 36.7,7.9 44.0,2.0",{"symbol":92,"name":93,"price":94,"change":95,"pct_change":96,"is_up":14,"sparkline":97,"date":5},"TSLA","Tesla Inc",377.75,-2.93,-0.77,"0.0,16.0 7.3,15.0 14.7,15.4 22.0,7.1 29.3,3.0 36.7,2.0 44.0,3.5",[99,104,109,114,119,124,129,134,139,143,148],{"name":100,"etf":101,"change":102,"price":103,"is_up":14},"Technology","XLK",-0.3,201.39,{"name":105,"etf":106,"change":107,"price":108,"is_up":14},"Financials","XLF",-0.48,53.75,{"name":110,"etf":111,"change":112,"price":113,"is_up":74},"Healthcare","XLV",1.03,168.81,{"name":115,"etf":116,"change":117,"price":118,"is_up":14},"Consumer Cycl","XLY",-0.32,111.36,{"name":120,"etf":121,"change":122,"price":123,"is_up":14},"Consumer Staples","XLP",-0.12,81.7,{"name":125,"etf":126,"change":127,"price":128,"is_up":14},"Energy","XLE",-0.58,63.38,{"name":130,"etf":131,"change":132,"price":133,"is_up":14},"Industrials","XLI",-2.18,167.84,{"name":135,"etf":136,"change":137,"price":138,"is_up":14},"Materials","XLB",-1.51,48.98,{"name":140,"etf":141,"change":66,"price":142,"is_up":14},"Real Estate","XLRE",40.57,{"name":144,"etf":145,"change":146,"price":147,"is_up":14},"Utilities","XLU",-0.02,41.15,{"name":149,"etf":150,"change":151,"price":152,"is_up":14},"Comm Services","XLC",-0.35,111.26,[154,159,164,169],{"ticker":155,"name":156,"price":157,"change":158,"is_up":14},"SPY","SPDR S&P 500 ETF",777.22,-0.24,{"ticker":160,"name":161,"price":162,"change":163,"is_up":14},"QQQ","Invesco QQQ Trust",757.73,-0.25,{"ticker":165,"name":166,"price":167,"change":168,"is_up":14},"DIA","SPDR Dow Jones ETF",511.02,-0.69,{"ticker":170,"name":171,"price":172,"change":66,"is_up":14},"IWM","iShares Russell 2000",277.7,{"ticker":4,"count":174,"articles":175},12,[176,182,188,194,200,206,212,217,222,227,233,238],{"title":177,"link":178,"pubDate":179,"description":180,"source":181},"Pacira BioSciences (PCRX) Stock Looks Expensive Relative To Its Earnings Power - Simply Wall Street","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\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?oc=5","Tue, 29 Sep 2026 13:39:39 GMT","Pacira BioSciences (PCRX) Stock Looks Expensive Relative To Its Earnings Power Simply Wall Street","Simply Wall Street",{"title":183,"link":184,"pubDate":185,"description":186,"source":187},"Pacira BioSciences (PCRX) On Its Molteni Deal And The Undervalued Narrative - Yahoo Finance","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMingFBVV95cUxPMlY5eEdGOS1nTlpHRUxLZVRaRHdoREZGTVU0MS1hSGNPd3Q5RXlfZml0ZUszWlBUUmtZZjNpTjVTNGR5NXBYOXIxVmpfblN0aWU4XzNmbUxMbWEycDR4N3JpbGx5QzF5NDZfTlpzM1UzTDNhcmdFREI2U2RuUnBWbS1RZXRNTTRoTENocThOUlZHYXVfYXBzQTBLLUk5Zw?oc=5","Tue, 06 Oct 2026 20:08:29 GMT","Pacira BioSciences (PCRX) On Its Molteni Deal And The Undervalued Narrative Yahoo Finance","Yahoo Finance",{"title":189,"link":190,"pubDate":191,"description":192,"source":193},"A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivAFBVV95cUxPTjFLdkk2MmlvNV9oYzFZMWliR0hxai1ZcTF1YUNSdkI2T2swUU1FclRnLTkwdUt3a3dQSnV3UmNfQjZjUDFBaTNBYTg4RVhqNV9SdFNzNjRqMXhlUWVsMTk2eU5qam03S0FheGlLblMyUGthUUxwbXZIc0pCcXVDVEQ3UVlGdHJoeEhlenYwb1JIcF9lQWp1YmlVSm83a0N4el8ySnhfYmJFa1AwMl9FOUtNTGl3dnpkeVVnQw?oc=5","Mon, 05 Oct 2026 12:00:00 GMT","A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. Stock Titan","Stock Titan",{"title":195,"link":196,"pubDate":197,"description":198,"source":199},"Technical Reactions to PCRX Trends in Macro Strategies - Stock Traders Daily","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi0AFBVV95cUxNX1BjTHV6WEFnODB5T21iWXFORnNVZzNUcE1fQldXN2JGQ3pRc2JPdkxNY19FdGhacFprUm1NOFZKaXVuY2QzYXlyZFkwUUp5MW9TeG1MRlJrc3JPLUxDd1BmYTI1dDhMMk5QRHNkV2xyWmFnNEh1NWZPMjZQZWR3a3pDdWFhQTNqT2dxcEJ0VDZkWDd2VkhzdUl0S0l1TmZDaE5nVnQ1WFhacnM4Mk56bG9rLVUtVVh5c3NfTWdMY2NmbDJOcGFHbklUNktYTW9M?oc=5","Sat, 03 Oct 2026 08:12:02 GMT","Technical Reactions to PCRX Trends in Macro Strategies Stock Traders Daily","Stock Traders Daily",{"title":201,"link":202,"pubDate":203,"description":204,"source":205},"PCRX Maintained by Truist Securities -- Price Target Raised to $31 - GuruFocus","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiowFBVV95cUxNQk9wUEVwUC15Sm81MkljSWVfOWY1MWtIZTZpbzBJQWNnUTZkZXBjNzFTMFFGakRfMXYyR0VMSG9ZSVRqQUtLaXVMWXhfRDBmZlhqaFd3RUx0NUd3YUJIVTJYZVEzaXM4RjlGbG5VNzNGOUhjTHozdzZSbFo3dWxaRnVsRWtSTm53N3ZweDVEeTk2aEliY3lac2xZUHhHM2JnSnhn?oc=5","Wed, 07 Oct 2026 17:59:39 GMT","PCRX Maintained by Truist Securities -- Price Target Raised to $31 GuruFocus","GuruFocus",{"title":207,"link":208,"pubDate":209,"description":210,"source":211},"PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMirgFBVV95cUxQSEE2RGZfMm02UWFEWG1DQkxEOElrU3gyNGtnWDZFd05oUGpCdjNCV0U2OFV5UHN6S1hLcHNybmpaWVdrNjJwRDUzWWNfVi1MRWluR1hTdF9UY05aZ1ZVMVRubzlQSExDcDB3NWFyUWNYTzJQTThnaTF5MllLTE9iSF9sQXVReFFTMk5DWHpKQUxMWFZXU0FyMGpYRlk5ZVBKdnBoc25MWThHek9RSVE?oc=5","Tue, 06 Oct 2026 18:43:42 GMT","PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal Zacks Investment Research","Zacks Investment Research",{"title":213,"link":214,"pubDate":215,"description":216,"source":187},"PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Yahoo Finance","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMinwFBVV95cUxPR0RvRTBMd2JQbl9RaWJZcU1JUC1iTjNKSTRVSURkX3JCaXRJSmFVa21jbmx1bnB5UVQ4VUw4LVlvdDNURzFpMGhuejV4NDJ2RUlya01VWEpfUFd0Wlo3WncxMFVRSmx4NEE3UjY0YTBZTGh5ZldiVnZXaVlTbHRrSlh2ckJZeTlvUHNORkoxdjNVWjB2bmQwWFpmNlFiODg?oc=5","Tue, 06 Oct 2026 13:30:00 GMT","PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal Yahoo Finance",{"title":218,"link":219,"pubDate":220,"description":221,"source":193},"76% of surveyed caregivers worried about the first days of home recovery - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwAFBVV95cUxPLWNTQk9PU3RWSDF6cHNTSDFKemZ1ZEVyVXA4NVZIR0M3cTMxdGhTb3lISkk4aGlzV1FlVkYwX2syRkpBbDh4akRzOEFtVnFmQTJjWUQtUkw4c3lwTDRrZnpZaVItYU9fTHZQZlFSc3BGNTBFUXVwclBQX1R0R3JGbDdNTTQ4WGJ0dGNpcWMySTZWSHVrMWZOcmJyMVFZVXFOR3E3amt4eUQ1VF9jSGpjTHlxT25UbGV6cUZjV2ZDVkc?oc=5","Wed, 07 Oct 2026 12:00:00 GMT","76% of surveyed caregivers worried about the first days of home recovery Stock Titan",{"title":223,"link":224,"pubDate":225,"description":226,"source":181},"How Investors Are Reacting To Pacira BioSciences Stock Europe Distribution Deal - Simply Wall Street","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi5wFBVV95cUxOOWRlNmN5azBYWUdoQTFMUy1ydmI4WXJCcTJqdkJrR2ZYZTVQOFlsV2tYNXBuLXh4dW1PQkk1U1JWc1hYa1R5aHhXMlYtSFhMM2p6Q3JZZG04VWdIdFFJbW9WTWlVenczajZmcDY2cDdZbXFfRTJPMG92dko0RU1QSE05UWdRalZ6S05fSk9OeWJxaUdiQUtEdHFPMjBCVmJ6OTZQZnlvNk5BUUtyTWNkbFZUOWw3UTFzSHo1ZU0xR3QtS3gxQXFITUdMUFM0dFBwYkRpazcxZm5TdG42QW9aeDMyek9jMG_SAewBQVVfeXFMTm43Vi16UkFTZUltdS1ET0ZDd1o4R3F5aGp1QnBfUmhwT2hZdllpaFRRTk1JX3JmejNzWFhEMzNqUWdTdUk5SnBxWkFYdGVpRHlGUEdLVlJ2UVd4Rlg4bnBXRTZ4eEJzNXJjLTBOTWRKMHN1emQ0ZXNoeUZVOEFlVjJ3QnZHX21KaWJzeGFoRkNJMnUwSFB1MTl3SHliRzVTckxBdWl3d0RnbUxRd3ZfQlJsaEdZMjNoUU9jNDFFZExtVjAtNnVsTFpiOS1LRU1NYVBfMVo1dE9tQkJDbkVPbmppX2VuRzFoZTUzX1g?oc=5","Wed, 07 Oct 2026 01:31:55 GMT","How Investors Are Reacting To Pacira BioSciences Stock Europe Distribution Deal Simply Wall Street",{"title":228,"link":229,"pubDate":230,"description":231,"source":232},"Pacira BioSciences partners with Molteni for European expansion By Investing.com - Investing.com South Africa","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxPeDd0SmJ4VENwc0tkRG9oaW9ySTZGYkhWUlNjcW01bWpzOVY0dnpwMFdJSXl0eHZVY2pUVGxLYmZBVnFEUlFtWEUwUXNCYUUxSXhwQjdhaW1Jb1hkYUVmc1FPUW8tU2xqc1M4anB3MHQyVjl4Z1FkcHZkNFpvYlZNZkkzU3J0NjhMcEV0RkZ2Q3llQVpEZ2RnZGxwUE50Z1ZPbUZyVzVHYTB5dkRGakc3a0ZIa2M4dlNHQ1BjdXZOU2FwUQ?oc=5","Tue, 06 Oct 2026 03:50:28 GMT","Pacira BioSciences partners with Molteni for European expansion By Investing.com Investing.com South Africa","Investing.com South Africa",{"title":234,"link":235,"pubDate":236,"description":237,"source":181},"Is Pacira BioSciences (PCRX) Undervalued On Its Molteni EXPAREL Distribution Deal? - Simply Wall Street","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\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?oc=5","Thu, 08 Oct 2026 06:01:44 GMT","Is Pacira BioSciences (PCRX) Undervalued On Its Molteni EXPAREL Distribution Deal? Simply Wall Street",{"title":239,"link":240,"pubDate":241,"description":242,"source":243},"Pacira BioSciences stock weighs Q2 growth and lower guidance - AD HOC NEWS","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwAFBVV95cUxOM2t0Qzl1Z3h4cW1FZHU5QmVwY2FNQlZEUVRudE1nMUVMM2VzZ1U3dHZmYnRFejhINDBrYUdPQWdHVmQ1WUt4eXV0RGEzeE5acnl6Vzl0NmNrWFVRVzdVT3d5RlZtejQ1d1QxQzRvbTM3Q0FOQzc5NUhVZVlCQ3NhZlRhNzRQVG0tdkJlUWktZVZxZEZOT1R1OFNmN1Rfd3BKTG1NUmRJWXlHM1dWTDViNFROeGdIcGpQLVFEQ2NFODg?oc=5","Sun, 04 Oct 2026 10:44:03 GMT","Pacira BioSciences stock weighs Q2 growth and lower guidance AD HOC NEWS","AD HOC NEWS"]